Research on treatments for idiopathic pulmonary fibrosis (ipf) is ongoing, with some outlets reporting on phase 3 trials of inhaled treprostinil, which may improve outcomes for ipf patients. Other companies, including celea therapeutics and oorja bio, are also conducting phase 3 trials for ipf treatments. The status and outcomes of these trials are not uniformly reported, suggesting that developments in ipf treatment are still emerging.